New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection

被引：18
作者：
Ceccarelli, Manuela [1 ,2 ]
Rullo, Emmanuele Venanzi [3 ]
Berretta, Massimiliano [3 ]
Cacopardo, Bruno [1 ]
Pellicano, Giovanni Francesco [4 ]
Nunnari, Giuseppe [3 ]
Guarneri, Claudio [2 ]
机构：
[1] Univ Catania, Dept Clin & Expt Med, Unit Infect Dis, Catania, Italy
[2] Univ Messina, Dept Biomed & Dent Sci & Morpho Funct Imaging, Messina, Italy
[3] Univ Messina, Dept Clin & Expt Med, Unit Infect Dis, Messina, Italy
[4] Univ Messina, Dept Adult & Childhood Human Pathol Gaetano Barre, Messina, Italy
来源：
DERMATOLOGIC THERAPY | 2021年 / 34卷 / 01期
关键词：
infection; interleukin‐ 17; 23; psoriasis; psoriatic arthritis; SARS‐ CoV‐ 2; SERIOUS INFECTIONS; PLAQUE PSORIASIS; CLOSTRIDIUM-DIFFICILE; SAFETY; MULTICENTER; COVID-19; CHILDREN; RISANKIZUMAB; GUSELKUMAB; EFFICACY;
D O I：
10.1111/dth.14660
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Psoriasis is a chronic immune-mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life-long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL-23/IL-17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.
引用
收藏
页数：7
相关论文
共 55 条
  • [41] Colitis-Induced Th17 Cells Increase the Risk for Severe Subsequent Clostridium difficile Infection
    Saleh, Mahmoud M.
    Frisbee, Alyse L.
    Leslie, Jhansi L.
    Buonomo, Erica L.
    Cowardin, Carrie A.
    Ma, Jennie Z.
    Simpson, Morgan E.
    Scully, Kenneth W.
    Abhyankar, Mayuresh M.
    Petri, William A., Jr.
    [J]. CELL HOST & MICROBE, 2019, 25 (05) : 756 - +
  • [42] Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
    Saunte, D. M.
    Mrowietz, U.
    Puig, L.
    Zachariae, C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (01) : 47 - 62
  • [43] Sbidian E, 2020, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011535.pub3, 10.1002/14651858.CD011535.pub2]
  • [44] Biologics for the primary care physician: Review and treatment of psoriasis
    Schadler, Eric D.
    Ortel, Bernhard
    Mehlis, Stephanie L.
    [J]. DM DISEASE-A-MONTH, 2019, 65 (03): : 51 - 90
  • [45] Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic
    Shah, Payal
    Zampella, John G.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (06) : E203 - E204
  • [46] Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity
    Shanshal, Mohammed
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (04) : 322 - 323
  • [47] Trends in Incidence and Outcomes of Clostridium difficile Colitis in Hospitalized Patients of Febrile Neutropenia A Nationwide Analysis
    Siddiqui, Nauman S.
    Khan, Zubair
    Khan, Mohammad S.
    Khan, Zarmina
    Haq, Khwaja F.
    Solanki, Shantanu D.
    Munigala, Satish
    Khan, Muhammad A.
    Saif, Muhammad W.
    Nawras, Ali
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2019, 53 (09) : e376 - e381
  • [48] Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
    Suleiman, Ahmed A.
    Khatri, Amit
    Oberoi, Rajneet K.
    Othman, Ahmed A.
    [J]. CLINICAL PHARMACOKINETICS, 2020, 59 (05) : 575 - 589
  • [49] Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom
    Takeshita, Junko
    Shin, Daniel B.
    Ogdie, Alexis
    Gelfand, Joel M.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (08) : 1726 - 1735
  • [50] Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy
    Talamonti, M.
    Galluzzo, M.
    Chiricozzi, A.
    Quaglino, P.
    Fabbrocini, G.
    Gisondi, P.
    Marzano, A. V.
    Potenza, C.
    Conti, A.
    Parodi, A.
    Fortina, A. Belloni
    Bardazzi, F.
    Argenziano, G.
    Rongioletti, F.
    Stingeni, L.
    Micali, G.
    Loconsole, F.
    Venturini, M.
    Bongiorno, M. R.
    Feliciani, C.
    Rubegni, P.
    Amerio, P.
    Fargnoli, M. C.
    Pigatto, P.
    Savoia, P.
    Nistico, S. P.
    Giustini, S.
    Carugno, A.
    Cannavo, S. P.
    Rech, G.
    Prignano, F.
    Offidani, A.
    Lombardo, M.
    Zalaudek, I.
    Bianchi, L.
    Peris, K.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (12) : E770 - E772
123456